Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.

Revenue
+3.07%
EPS
−13.5%
Free cash flow
+29.8%
Total debt
−7.50%

Quarter to September 2026, against a year earlier

105.28 1.57 −1.47%
Market cap
$20.4B
P/E
26.5×
Fwd P/E
18.9×
Dividend yield
0.91%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100

Zimmer Biomet Holdings, Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:05 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 3 added · 3 removed · 32 modified; 4 with only figures updated

  1. Modified · Results for the Three and Nine-Month Periods ended September 30, 2026

    In the three and six-monthnine-month periods ended JuneSeptember 30, 2026, our net sales increased 4.83.1 percent and 7.05.7 percent, respectively, when compared to the same prior year periods. Net sales growth was driven by a combination of our Paragon 28 acquisition, positive effects of changesopportunistic end-of-quarter customer purchases; the 2026 acquisitions; growth in foreign currency exchange rates, opportunistic end-of-quarter customer purchasessales of our foot and ankle, increased ROSA® Robot and bone cement sales,products; market growth; and new product introductions. In addition, Paragon 28 had a positive impact on our net sales of 0.71.5 percent and 2.3 percent in the three and six-month periods nine-month period ended JuneSeptember 30, 2026, respectively. Additionally, our net sales experienced a positivenegative effect of 0.10.6 percent and 1.3 a positive effect of 0.7 percent from changes in foreign currency exchange rates in the three and six-monthnine-month periods ended JuneSeptember 30, 2026, respectively.

37 more changes in this Item, word by word, in Powerpack.